617 completed, 155 terminated, 72 active not recruiting, 49 withdrawn. 600 Phase 1, 338 Phase 2, 36 Not applicable, 21 Phase 3, 4 Early Phase 1.
Follow this drug Literature Review of Pharmacological Study trials Research Report on Pharmacological Study
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma Yttrium Y 90 Basiliximab, Carmustine, Etoposide - Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 20 | 2020-06-08 | 2025-03-20 |
| Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer Biospecimen Collection, Brachytherapy, Cisplatin - Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2019-09-18 | 2026-07-31 |
| Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial Laboratory Biomarker Analysis, Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, Pharmacological Study - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Mayo Clinic | 9 | 2019-04-25 | 2023-06-15 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 72 | 2019-01-31 | 2026-09-18 |
| Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab - Pleural Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2018-10-04 | 2026-10-15 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 23 | 2018-09-24 | 2026-04-29 |
| Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant Laboratory Biomarker Analysis, Melphalan Hydrochloride, Pharmacological Study - Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma | Phase 2 | Withdrawn | Ohio State University Comprehensive Cancer Center | 2018-09-01 | 2020-02-21 | |
| Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Daratumumab, Ibrutinib, Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia | Phase 1 | Completed | Jennifer Woyach | 15 | 2018-08-16 | 2026-06-15 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis Biopsy, Biospecimen Collection, Computed Tomography - Cirrhosis | Phase 1 | Unknown | National Cancer Institute (NCI) | 14 | 2018-08-09 | 2024-08-02 |
| Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) Birinapant, Carboplatin, Laboratory Biomarker Analysis - High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2018-08-01 | 2025-05-13 | |
| STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain Laboratory Biomarker Analysis, Pharmacological Study, STAT3 Inhibitor WP1066 - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 8 | 2018-07-13 | 2022-03-23 |
| Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Laboratory Biomarker Analysis - Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 6 | 2018-06-14 | 2021-04-02 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer 6,8-Bis(benzylthio)octanoic Acid, Docetaxel, Pharmacological Study - Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7 | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2018-06-01 | 2018-08-01 | |
| ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment Laboratory Biomarker Analysis, Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet, Pharmacological Study - Oral Cavity Neoplasm, Oropharyngeal Neoplasm | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2018-05-31 | 2023-03-08 |
| Terameprocol in Treating Patients With Recurrent High Grade Glioma Terameprocol, Pharmacological Study - High Grade Glioma (III or IV) | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 20 | 2018-05-03 | 2023-10-06 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-04-20 | 2018-07-18 | |
| Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Cytarabine, Idarubicin, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 53 | 2018-04-18 | 2026-06-01 |
Showing 20 of 920. Sign in to see all of them.
Breast Neoplasms (88) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (88) · Leukemia, Lymphocytic, Chronic, B-Cell (72) · Leukemia, Myeloid, Acute (72) · Glioblastoma (67) · Burkitt Lymphoma (60) · Lymphoma, Large B-Cell, Diffuse (60) · Gliosarcoma (59) · Lymphoma, Mantle-Cell (55) · Lymphoma, Follicular (54) · Lymphoma, Non-Hodgkin (53) · Astrocytoma (52) · Brain Neoplasms (51) · Carcinoma, Non-Small-Cell Lung (51) · Lymphoma, B-Cell, Marginal Zone (50)
National Cancer Institute (NCI) (448) · City of Hope Medical Center (56) · Roswell Park Cancer Institute (44) · Mayo Clinic (35) · M.D. Anderson Cancer Center (31) · Children's Oncology Group (29) · Fred Hutchinson Cancer Center (17) · Cancer Research UK (15) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (15) · Northwestern University (10) · Jonsson Comprehensive Cancer Center (9) · OHSU Knight Cancer Institute (9) · University of Southern California (9) · University of Washington (9) · Vanderbilt-Ingram Cancer Center (9)
United States (815) · Canada (86) · United Kingdom (32) · Australia (21) · France (17) · Puerto Rico (15) · New Zealand (12) · Germany (6) · Singapore (6) · Ireland (5) · Netherlands (5) · Switzerland (5) · Belgium (4) · Italy (3) · Japan (3)
Alex Adjei (6) · George Wilding (6) · Patricia LoRusso (6) · Stuart A. Grossman, MD (5) · Wen Wee Ma (5) · Amar Gajjar (4) · Brenda Sandmaier (4) · Ivana Gojo (4) · Jana Portnow, MD (4) · Kristie Blum (4) · Saby George (4) · Stephen Michael Hahn (4) · Suresh Ramalingam (4) · William Blum (4) · Andrea E Wahner Hendrickson (3)
PMID 31401903, PMID 32499241, PMID 36184192, PMID 23660685, PMID 26169613, PMID 32623479, PMID 33852135, PMID 34608724, PMID 37344887, PMID 41920422, PMID 14520092, PMID 17551310, PMID 17679729, PMID 17693647, PMID 18245546, PMID 18359865, PMID 18523152, PMID 18757332, PMID 18797458, PMID 19364967, PMID 19768386, PMID 19850643, PMID 20012293, PMID 20368434, PMID 20460632, PMID 20471824, PMID 20522709, PMID 20876255, PMID 20879881, PMID 20967484, PMID 21239698, PMID 21247755, PMID 21285985, PMID 21321091, PMID 21465636, PMID 21632852, PMID 21850464, PMID 21992853, PMID 22088484, PMID 22259028, PMID 22291006, PMID 22293631, PMID 22323663, PMID 22347360, PMID 22394984, PMID 22448921, PMID 22517399, PMID 22566605, PMID 22766773, PMID 22915661
P30CA015083 (33), U01CA076576 (30), P30CA033572 (28), U01CA062505 (28), U10CA098543 (26), U01CA097452 (25), U10CA180886 (21), U01CA070095 (20), P30CA015704 (19), P30CA016058 (19), P30CA016672 (19), U01CA062491 (19), U01CA099168 (19), U01CA062490 (18), P30CA006973 (16)